Market Place
Sourcing Support
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia
19 Mar 2024 //
PR NEWSWIRE
American Regent Announces Results From Phase 3 HEART-FID Trial with INJECTAFER®
26 Aug 2023 //
BUSINESSWIRE
Daiichi Sankyo scores first nod for IV iron replacement drug in patients
06 Jun 2023 //
ENDPTS
Emcure to launch the750 mg injectable variant of ferric carboxymaltose
17 May 2023 //
INDIAN PHARMA POST
Ferinject approved in China for the treatment of iron deficiency in patients
28 Nov 2022 //
PHARMTECH
Ferinject approved in Chinafor the treatment of iron deficiency in patients
28 Nov 2022 //
BUSINESSWIRE
FDA Confirms Paragraph IV Patent Litigation for Ferric Carboxymaltose Inj
19 Nov 2022 //
FDA
FDA Confirms Para IV Patent Litigation for Ferric Carboxymaltose Injection
06 Apr 2022 //
FDA
Vifor, American Regent announce settlement of Injectafer patent litigation
19 Dec 2021 //
BUSINESSWIRE
Vifor`s Ferinject® granted new recommendations in ESC heart failure guidelines
31 Aug 2021 //
BUSINESSWIRE
Injectafer® (ferric carboxymaltose inj) Receives FDA Approval for Single Dose
06 May 2021 //
PRNEWSWIRE
Vifor`s Ferinject misses target in heart failure trial
24 Sep 2020 //
REUTERS
Vifor Pharma announces outcome of AFFIRM-AHF topline data
23 Sep 2020 //
BUSINESSWIRE
Ferric carboxymaltose methodology
11 Feb 2020 //
PRESS RELEASE
Ferric carboxymaltose methodology
11 Feb 2020 //
PRESS RELEASE
Daiichi Sankyo US subsidiary, Luitpold Pharma to merge with its own subsidiaries
30 May 2018 //
PHARMABIZ
Daiichi Sankyo partners with Crohn’s & Colitis Foundation to draw attention
02 Apr 2018 //
FIERCE PHARMA
Review: Intravenous iron-containing medicinal products
22 Mar 2017 //
EMA
Pharma firms fall foul of ABPI Code
15 Mar 2017 //
PHARMATIMES
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.